In anemia of chronic disease, the initial treatment — oral iron combined with management of the underlying disease — is expected to produce a measurable rise in hemoglobin within two weeks. When that response is absent, or when oral therapy is not tolerated or feasible, the clinical situation calls for a structured next-line approach.
The first-line approach uses oral iron preparations (iron salts or iron carbohydrates), taken together with treatment of the underlying disease. The expected outcome is a confirmed increase in hemoglobin, reassessed after two weeks — a successful response also confirms absolute iron deficiency. Escalation to the next protocol is triggered when that hemoglobin rise is not achieved, when gastrointestinal intolerance to oral iron develops, when gastrointestinal uptake is impaired, or when a short timeline before planned surgery requires a faster result.
This protocol moves to intravenous iron therapy. Several formulations exist, varying in their capacity for single-dose iron delivery. The clinical goal is successful correction of iron deficiency. Formulation selection, dosing parameters, and the full structured algorithm are available in the complete protocol.
DOI: 10.1016/j.kint.2025.06.006
IV iron therapy is indicated when oral iron treatment is insufficient to correct iron deficiency, such as during ongoing blood loss in dysfunctional uterine bleeding or multiple vascular malformations in the gastrointestinal tract, in the presence of gastrointestinal side effects, or when a rapid replenishment of iron stores is desired, such as prior to a planned surgery.
In addition to older IV iron-carbohydrate formulations, such as ferric gluconate or ferric sucrose, newer glycan-coated nanoparticle drugs, such as iron carboxymaltose, iron isomaltoside, and ferumoxytol, have been introduced into clinical practice, which allow administration of up to 1000 mg of iron per injection.
View source ↗